A Controlled Clinical Study of Endostar/PD-1 Inhibitors Combined With PP as First-line Treatment for Advanced Non-squamous Cell Lung Cancer With Negative Driving Gene

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 14 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Endostatin (Primary) ; Sintilimab (Primary) ; Carboplatin; Cisplatin; Pemetrexed
Indications Non-small cell lung cancer
Focus Therapeutic Use
Acronyms ENPOWER

07 Jun 2022 Results assessing Three days of CIV rh-Endostatin in combination with PD-1 antibody plus chemotherapy, presented at the 58th Annual Meeting of the American Society of Clinical Oncology
07 Jun 2022 According to a Simcere Pharmaceutical Group media release, results from this trial were presented at the 2022 annual meeting of American Society of Clinical Oncology (ASCO).
07 Jun 2022 Results published in the Simcere Pharmaceutical Group Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com